UR9.F Clinuvel Pharmaceuticals Limited
- Market cap
- EUR 231M
- P/E
- 11.7x
- P/B
- 1.37x
- ROE
- 12.4%
- Dividend yield
- 0.69%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is UR9.F undervalued?
Graham numberUR9.F trades 15.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clinuvel Pharmaceuticals Limited fundamental analysis
No fundamental analysis for Clinuvel Pharmaceuticals Limited yet.
Clinuvel Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…
Full company profileClinuvel Pharmaceuticals Limited financial statements
Clinuvel Pharmaceuticals Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.21M | 16.7M | 25.5M | 31.0M | 32.6M | 65.7M | 78.3M | 88.2M | 95.0M | 94.0M |
| Gross Profit | 2.48M | 12.7M | 19.5M | 24.2M | 22.9M | 55.2M | 69.5M | 78.1M | 79.1M | 78.2M |
| Operating Income | -4.16M | 6.75M | 12.2M | 16.7M | 11.8M | 35.3M | 44.1M | 48.0M | 45.7M | 39.5M |
| EBITDA | - | - | - | - | - | - | 49.6M | 56.3M | 57.2M | 40.5M |
| Net Income | -3.15M | 7.18M | 13.2M | 18.1M | 16.6M | 20.9M | 30.6M | 35.6M | 36.2M | 33.9M |
| EPS | - | - | - | - | - | 0.42 | 0.62 | 0.71 | 0.72 | 0.67 |
| Balance Sheet | ||||||||||
| Total Assets | 20.1M | 28.6M | 42.9M | 62.3M | 81.5M | 144M | 194M | 231M | 272M | 295M |
| Total Liabilities | 2.30M | 3.16M | 3.49M | 5.17M | 7.87M | 18.4M | 29.1M | 28.1M | 30.9M | 22.2M |
| Shareholders' Equity | 17.8M | 25.4M | 39.4M | 57.2M | 73.7M | 126M | 165M | 203M | 241M | 273M |
| Cash & Short-term Investments | 13.8M | 23.8M | 36.2M | 54.3M | 66.7M | 122M | 157M | 184M | 224M | 252M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.04M | 9.92M | 11.7M | 18.5M | 14.2M | - | - | - | - | - |
| Capital Expenditure | 98.1K | 67.5K | 75.1K | 258K | 889K | 434K | 1.03M | 5.58M | 299K | 1.60M |
| Free Cash Flow | - | - | - | - | - | 39.4M | 35.9M | 31.5M | 40.8M | 35.3M |
| Ratios | ||||||||||
| ROE | -17.7% | 28.3% | 33.6% | 31.7% | 22.6% | 16.6% | 18.6% | 17.6% | 15.0% | 12.4% |
| ROA | -15.7% | 25.1% | 30.8% | 29.1% | 20.4% | 14.5% | 15.8% | 15.4% | 13.3% | 11.5% |
| Net Profit Margin | -50.8% | 42.9% | 51.9% | 58.4% | 51.1% | 31.8% | 39.1% | 40.4% | 38.1% | 36.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Clinuvel Pharmaceuticals Limited dividends
- Dividend yield
- 0.69%
- Forward dividend
- 0.03 EUR
- Payout ratio
- 7.4%
- Ex-dividend date
- Sep 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 2.51M | 0.05 | 7.4% |
| 2025 | AUD 2.50M | 0.05 | 6.9% |
| 2024 | AUD 2.47M | 0.05 | 6.9% |
| 2023 | AUD 1.98M | 0.04 | 6.5% |
| 2022 | AUD 1.24M | 0.03 | 5.9% |
| 2020 | AUD 1.22M | - | 7.4% |
| 2019 | AUD 957K | - | 5.3% |
| 2018 | AUD 957K | - | 7.2% |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 12, 2010.
Who owns Clinuvel Pharmaceuticals Limited
- Insiders 16.57%
- Institutions 13.26%
- Public & others 70.16%
- Shares outstanding 50.5M
- Free float 44.0M
Clinuvel Pharmaceuticals Limited company profile
- Company name
- Clinuvel Pharmaceuticals Limited
- Ticker
- UR9.F
- ISIN
- AU000000CUV3
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 535 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9660 4900
- Website
- clinuvel.com
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Limited management
9- Dr. Philippe Jacques Wolgen M.B.A., M.D.CEO, MD & Director · born 1963
- Mr. Peter VaughanChief Financial Officer
- Mr. Lachlan HayChief Operations Officer
- Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.Chief Scientific Officer
- Mr. Malcolm BullHead of Australian Operations & Investor Relations
- Dr. Azza HamilaHead of Quality Assurance & Drug Safety
- Ms. Claire Newstead-Sinclair C.A.Company Secretary
- Dr. Linda TengDirector of North American Operations
- Dr. Emilie RodenburgerDirector of Global Clinical Affairs